

# Flash Comment

## **Total Brain**

## Binding agreement to sell assets to SonderMind

Total Brain (ASX:TTB) is the developer of a neuroscience-based mental health and fitness platform powered by the largest standardized neuroscientific database in the world formed over almost two decades. The company has announced that it has reached a binding agreement to sell its assets to US private-equity backed group SonderMind for US\$10m. The purchase price is less: any debt-funding provided by SonderMind to underpin Total Brain's working capital requirements until completion of the proposed transaction; the value of assumed employee entitlements for those employees who accept SonderMind's offer of employment; and an agreed adjustment of approximately US\$0.133m in tax liabilities. SonderMind has already made available US\$0.5m to Total Brain via a letter of credit which the company has fully drawn and an additional US\$2.0m may be made available to the company should funds be required prior to completion. Subject to shareholder approval of the sale, the company intends to pay out outstanding liabilities and fees, including the \$1.28m convertible note held by shareholder Zoltan Varga, and following these payments, conduct a share-buyback to enable shareholders to liquidate their investment in the company. On completion of the share buyback, Total Brain will apply to the ASX for de-listing and commence the winding-up process. The directors of the company have unanimously recommended that Total Brain shareholders vote in favour of the proposed transaction.

### **Business** model

Total Brain operates a Subscription-as-a-Service (SaaS) model for its mental health and fitness platform. The science behind the platform has been developed over almost two decades with input from the leading academic institutions in the field. This has generated a proprietary neuroscientific database of scale which underpins the scientific validation that differentiates Total Brain from other brain training and wellness applications. The app, promoted by affinity partners, assesses the four core brain capacities (emotion, feeling, cognition, self-control), pre-screens seven common mental health conditions and delivers personalised brain and mind/body training.

## Recent Q4 Performance

Total Brain recently reported Q4 FY22 cash receipts of \$1.56m and net operating cashflow of \$1.2m, assisted by \$2.37m in government grants. Operating cash receipts were down 3% year-on-year and 5% quarter-on-quarter. FY22 cash receipts were \$7.7m and the net operating cash outflow for the year was \$1.97m. The company ended the quarter with net debt of \$0.56m. The company noted that during the quarter, it had renewed four population health clients representing US\$0.59m in Annual Recurring Revenues (ARR). This included the five-year contract extension with the American Association of Retired Persons (AARP) which delivered total recurring revenues of US\$2.7m over the contract term.

## **Next Steps**

Total Brain will despatch a notice of meeting to shareholders and Independent Expert's Report to shareholders by mid-August with the view to holding an Extraordinary General Meeting in mid-September for completion of the proposed transaction in late September. The proposed transaction is subject to a number of conditions which need to be satisfied or waived including approval of the transaction by TTB shareholders, no breach of warranty by either SonderMind or Total Brain, no material adverse change occurring in relation to TTB's business, third-party consents to assign or novate contracts to SonderMind, key employees accepting employment with SonderMind, no insolvency event occurring within the TTB group, and agreement of the terms on which interim funding is provided by SonderMind to the company.

## 8 August 2022

Share Details	
ASX code	TTB
Share price (intraday)	\$0.046
Market capitalisation	\$6.1M
Number of shares	133.4M
Net debt (30 June 2022)	\$0.56M
Sector	Heathcare Services
Free float	~57%
Share Price Performance (12-months)	
50.30 50.25 50.10 50.05	
Company Contact	

### Company Contact

Simon Poidevin simon.poidevin@totalbrain.com (President Australia/NZ)

## **RaaS Advisory Contact**

Finola Burke\* +61 414 354 712 finola.burke@raasgroup.com

\*The analyst and RaaS Advisory hold shares



# FINANCIAL SERVICES GUIDE

RaaS Advisory Pty Ltd
ABN 99 614 783 363
Corporate Authorised Representative, number 1248415

of

BR SECURITIES AUSTRALIA PTY LTD
ABN 92 168 734 530
AFSL 456663

Effective Date: 6<sup>th</sup> May 2021



#### About Us

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License ("AFSL") number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR.

This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS's services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Suite 5GB, Level 5, 33 Queen Street, Brisbane, QLD, 4000

RaaS. 20 Halls Road Arcadia. NSW 2159

P: +61 414 354712

E: finola.burke@raasgroup.com

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

What Financial Services are we authorised to provide? RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
  - Securities
- deal on behalf of retail and wholesale clients in relation to
  - Securities

The distribution of this FSG by RaaS is authorized by BR.

#### Our general advice service

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

## Our dealing service

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application form if needed.

## How are we paid?

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

## **Associations and Relationships**

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS's representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

## Complaints

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR's internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren't satisfied with an outcome, you may contact AFCA, see below.

BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: <a href="www.afca.org.au">www.afca.org.au</a>; Email: <a href="mailto:info@afca.org.au">info@afca.org.au</a>; Telephone: 1800931678 (free call) In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

## **Professional Indemnity Insurance**

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.



## **DISCLAIMERS and DISCLOSURES**

This report has been commissioned by Total Brain Ltd prepared and issued by RaaS Advisory Pty Ltd. RaaS Advisory has been paid a fee to prepare this report. RaaS Advisory's principals, employees and associates may hold shares in companies that are covered and, if so, this will be clearly stated on the front page of each report. This research is issued in Australia by RaaS Advisory and any access to it should be read in conjunction with the Financial Services Guide on the preceding two pages. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. RaaS Advisory provides this financial advice as an honest and reasonable opinion held at a point in time about an investment's risk profile and merit and the information is provided by the RaaS Advisory in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. RaaS Advisory has no obligation to update the opinion unless RaaS Advisory is currently contracted to provide such an updated opinion. RaaS Advisory does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise. The science of climate change is common knowledge and its impacts may damage the global economy. Mitigating climate change may also disrupt the global economy. Investors need to make their own assessments and we disclaim any liability for the impact of either climate change or mitigating strategies on any investment we recommend.

Investors are responsible for their own investment decisions, unless a contract stipulates otherwise. RaaS Advisory does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, RaaS Advisory shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, RaaS Advisory limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable. Copyright 2022 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.